

BEST OF ASCO®

OFFICIALLY LICENSED

AMERICAN SOCIETY OF CLINICAL ONCOLOGY

BENGALURU, INDIA 2025

Theme:

**Driving Knowledge to Action:
Building a Better Future**

DELEGATE BROCHURE

23-24 August, 2025

Sheraton Brigade Gateway, Bengaluru

Endorsed by



Academia of Head & Neck
Oncology of Karnataka

Hosted by



GHA
GLOBAL HEALTHCARE
ACADEMY

GHA Hosts
“BEST OF ASCO”
back to where it
all began in
NAMMA
BENGALURU



BENGALURU - 2024

ASCO®

THROUGH THE YEARS

MUMBAI - 2024



ABOUT

BEST OF ASCO

Best of ASCO (American Society of Clinical Oncology) is an educational initiative aimed at discussing key highlights from ASCO's annual meeting. Hosted by GHA, this edition focuses on practice-changing therapies in cancer treatment. Aligned with the theme "Driving Knowledge to Action: Building a Better Future", the discourse explores the clinical scope of cancer research and trials, with special emphasis on immunotherapy. Despite promising data, applying these findings in clinical settings remains a challenge.

This event creates a powerful platform to discuss the specifics of immunotherapy and bifunctional antibody treatments across cancer types. Experts will share perspectives on emerging therapies, adverse effects, and the scientific reasoning behind their clinical use. Attendees can also engage in panel discussions and explore several curated sessions designed to inform, inspire, and connect. With rich opportunities for collaboration and learning,

we look forward to a thought-provoking and engaging event.

ABOUT

THE HOST

GLOBAL HEALTH CARE ACADEMY (GHA)

Transforming Healthcare Education with Tech and Expertise

Global Healthcare Academy (GHA) stands as India's pioneering Med-Ed Tech Academy, dedicated to building the future of healthcare. Our mission? **Empowering competent and compassionate professionals** who thrive in the ever-evolving medical landscape.

Bridging the Skills Gap:

We recognize the disconnect between traditional healthcare education and industry demands. GHA actively bridges this gap by:

- Leveraging technology: We integrate cutting-edge solutions throughout our learning process, enhancing engagement and accessibility.
- Faculty expertise: Our instructors are renowned medical professionals, blending academic knowledge with real-world experience.

- Case-based learning: We immerse students in real-life scenarios, fostering critical thinking and practical skills.
- Practice-oriented approach: Our methodologies equip graduates to hit the ground running, prepared to excel in their chosen fields.

A Multifaceted Learning Experience:

- GHA caters to diverse needs through five dedicated verticals:
- Allied Healthcare: Paramedical training programs to equip future healthcare assistants.
- Continuing Medical Education (CME): Upskilling and reskilling courses for healthcare professionals.
- Global Dental Academy (GDA): Specialized programs for aspiring and established dentists.
- Global Healthcare Publishing (GHP): Disseminating valuable knowledge through healthcare publications.
- GHA Conferences: Facilitating knowledge exchange and professional development through industry events.

Guided by Leaders, Driven by Passion:

GHA is led, managed, and advised by a renowned team of doctors and healthcare professionals, ensuring the highest standards of education and industry relevance.

ABOUT India

India, steeped in history and cultural diversity, boasts a legacy that predates many civilizations, dating back over 5,000 years. As one of the world's most ancient civilizations, it is a nation brimming with a kaleidoscope of traditions and a rich cultural heritage. Over the past 78 years since gaining independence, India has achieved remarkable progress in all aspects of society and economy. The nation has attained self-sufficiency in agriculture and risen as a global industrial powerhouse, even venturing into outer space.



Encompassing an expansive landmass of 3.28 million square kilometres, India spans from the snow-clad heights of the Himalayas to the lush tropical rainforests of the south. It stands out as the 7th largest country globally, distinguished by its unique geography with mountains to the north and seas to the south, creating a distinct geographical identity.

Journeying through this vast nation offers a wide spectrum of tourism choices, encompassing diverse landscapes, people, tribes, cuisines, faiths, dance forms, music, arts, and crafts, adventures, sports, spirituality, and history. Each state within India offers a unique tapestry of experiences, demonstrating the nation's remarkable diversity.

ABOUT HOST CITY

A multicultural city, Bangalore has experienced a dramatic social and cultural change with the advent of globalization and expansion of the information technology and business process outsourcing industries in India. Since the late 1990s, Bangalore has been known as the Silicon Valley of India and recently earned a new tag i.e. The Start-up Capital of India. Owing to its business-friendly environment a vast number of ex-pat population study, work, and live in India.

Bangalore, a city in southern India and the capital of the Indian state of Karnataka is the most sought-after healthcare destination within India with its unique social scenario, wide use of the English language, world-class healthcare infrastructure, and affordable healthcare, and connectivity with the rest of world. e-Medical visas are offered to medical tourists from 166 countries. This generous approach by the Government of India has helped needy patients from abroad to reach out to the Indian hospitals.

Hospitals in Bangalore are equipped with modern healthcare infrastructure and are on par with European and US hospitals. Healthcare professionals in Bangalore are well known for their skills and therapeutic care. The presence of such reputed healthcare providers makes medical tourism in bangalore (India) makes more attractive among foreign healthcare travellers.

Welcoming nature of the local residents of Bangalore made it the most cosmopolitan city in India.

CORE COMMITTEE MEMBERS



Dr. Aditya Murali
Medical Oncology



Dr. Amit Rauthan
Medical Oncology



Dr. M S Belliappa
Radiation Oncologist



Dr. Govind Babu
Medical Oncology



Prof. K.S. Gopinath
Surgical Oncology



Dr. Jagannath Dixit
Surgical Oncology



Dr. Kirthi Koushik A.S
Radiation Oncology



Dr. Mithua Ghosh
Molecular & Clinical Genomics



Dr. Nataraj K S
Haemato Oncology



Dr. Prasad Narayan
Medical Oncology



Prof. Ramesh S. Bilimagga
Radiation Oncology



Dr. Rakesh Jalali
Radiation Oncology



Dr. Shekar Patil
Medical Oncology



Dr. Sachin Trivedi
Medical Oncology



Dr. Suraj Manjunath
Surgical Oncology



Dr. Suresh Babu
Medical Oncology



Dr. Srinivas B J
Medical Oncology



Dr. Srinivas K G
Medical Oncology



Dr. Sai Vivek V
Medical Oncology



Dr. Vijay Agarwal
Medical Oncology



Dr. Vishal Rao
Surgical Oncology



Dr. Vikram Maiya
Radiation Oncology



Dr. Vinayak V Maka
Medical Oncology

DETAILS OF REGISTRATION

Registration Category	Regular Until 31 July 2025	Late Registration 01 August 2025 Onwards
Delegate (Members)	8,500	9,500
Delegate (Non-Members)	9,500	10,500
Delegate (AHS)	4,000	5,000
Post Graduate Student	3,500	4,500
Accompanying Person	3,500	4,500
Industry (Sponsor)	30,000	30,000
Student Group Registration	2,000	3,000

- The above-mentioned rates are inclusive of all applicable taxes.
- Members Association: ASCO, ISMPO, BOG, IASO, SOGO, AROI, AMOI, AOMSI, and AMPI.
- Members AHS: Onco-Nurses, Radiologists, Geneticists, Pharmacists, Molecular Biologists, Onco-Nutritionist & Others

CONFERENCE **WORKSHOPS**

- Postgraduate Exam Bootcamp: Skills, Strategy & Success.
- Research Methodology & Biostatistics Workshop: From Idea to Design
- Inside the Cell: Exploring the Power of Molecular Biology.
- Emerging Technologies in Oncology: The Role of Artificial Intelligence.

CALLING ALL ASPIRING ONCOLOGISTS!

SUBMISSION TOPICS ONCOLOGY:

Medical Oncology

Surgical Oncology

Radiation Oncology

SUB- SPECIALTY / FOCUS SESSIONS:

Onco Pathology

Onco Palliative Care

Research Methodology

Speech and Swallow

Regenerative Medicine

Yoga

Onco Nutrition

Precision Oncology &
Pharmacogenomics

SHOWCASE YOUR RESEARCH. GET RECOGNIZED. WIN PRIZE MONEY!

Paper Submission Deadline: 31 July, 2025

RECOGNITION & OPPORTUNITIES

- Attend and participate in the world's top oncology conferences
- Present at a prestigious cancer research platform
- Network with global oncology experts
- Explore career-building opportunities in oncology
- Get your Paper published in the *Journal of Precision Oncology*

JOURNAL OF
PRECISION ONCOLOGY



5

Best Paper Awards ₹ **25,000/-**

Best Poster Awards ₹ **15,000/-**



WHO SHOULD ATTEND

Medical Oncologists

Radiologists

Radiation Oncologists

Onco-Pathologists

Surgical Oncologists

Geneticists

Pediatric Oncologists

Pharmacists

Pyscho Oncologists

Researchers

Hemato oncologists


Onco-Nurses

Medical Students

Molecular Biologists

Onco-Nutritionist

Industry Representatives



OUR PAST SPONSORS



SHERATON GRAND BRIGADE GATEWAY, BANGALORE

23-24 AUGUST, 2025



- | | | | |
|--|--|---|---|
|  GBR 1 & 2
(Grand Ball Room) |  HALL - 3 |  HALL - 4 |  HALL - 5 |
|  HALL - 6 |  HALL - 7 (Advisory Board Meeting) | | |

DAY 1



23 August 2025 (Saturday)



08:00 – 17:00

SESSION HIGHLIGHTS

Time in Hrs (IST)	Track Code	Topics and Session Tracks
GBR - 1		
08:00 - 10:00	Pre Conference Workshop - 1	Postgraduate Exam Bootcamp: Skills, Strategy & Success
10:00 - 11:40	Scientific Session	Track: Breast Cancer - Metastatic
12:05 - 13:25	Scientific Session	Track: Breast Cancer - Local/Regional/Adjuvant
14:05 - 15:30	Scientific Session	Track: Head & Neck
GBR - 2		
08:00 - 10:00	Pre Conference Workshop - 2	Inside the Cell: Exploring the Power of Molecular Biology
HALL - 3		
09:00 - 13:00	BoA Award Paper	Award Paper Presentation - Best of ASCO, Bengaluru
14:05 - 15:35	Scientific Session	Track: Hematologic Malignancies
HALL - 4		
09:00 - 17:00	Focus Session 1	Onco-Pathology
HALL - 5		
09:00 - 13:00	Focus Session 2	Onco Palliative
14:00 - 17:00	Focus Session 3	Regenerative Medicine
HALL - 6		
09:00 - 13:00	Focus Session 4	Onco Pharma; Genomics & Precision Oncology
14:00 - 17:00	Focus Session 5	Speech & swallow

GBR 1

Session 01 | Track: (i) Breast Cancer - Metastatic

Chairperson: TBD

10:00 - 11:10	MBC PLENARY (10 MINS)	LBA4	Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. TBD
	MBC (5 MINS)	1001	Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator's choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial. TBD
	MBC (5 MINS)	1003	"INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC)." TBD
	MBC (5 MINS)	1009	Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial). TBD
	MBC (5 MINS)	1013	Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINYBreast06 (DB-06). TBD
	MBC (5 MINS)	1015	Treatment rechallenge after trastuzumab deruxtecan related interstitial lung disease: A multi-institution cohort study. TBD
	MBC (5 MINS)	1030	Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort. TBD
	MBC (5 MINS)	1039 / 1040	Risk of radiation necrosis with concurrent antibody-drug conjugates and radiotherapy in HER2-positive breast cancer with brain metastases: A metaanalysis. / Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC). TBD
	MBC (5 MINS)	LBA1000	Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. TBD

	MBC (5 MINS)	LBA1005	A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581). TBD
	MBC (5 MINS)	LBA1008	Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09. TBD
	MBC (5 MINS)	LBA109	Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. TBD
	MBC (5 MINS)		TBD
11:10 - 11:20	IT (10 MINS)		Invited Talk

Moderators: TBD

11:20 - 11:40	PD (20 MINS)		Panel Discussion: Track: (i) Breast Cancer - Metastatic TBD
11:40 - 11:50	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

11:50 - 12:05	(15 MINS)	TEA BREAK	
---------------	-----------	------------------	--

Session 02 | Track: (i) Breast Cancer - Local / Regional / Adjuvant

Chairperson: TBD

12:05 - 12:55	LABC (5 MINS)	501	Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial. TBD
	LABC (5 MINS)	504	Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial. TBD
	LABC (5 MINS)	505	15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS. TBD

12:05 - 12:55	LABC (5 MINS)	507	The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study. TBD
	LABC (5 MINS)	508	Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial. TBD
	LABC (5 MINS)	511	A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. TBD
	LABC (5 MINS)	521	The effect of endocrine therapy omission on survival in ER-negative PR-low (1–10%) early-stage breast cancer treated with chemotherapy. TBD
	LABC (5 MINS)	LBA500	De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial. TBD
	LABC (5 MINS)	LBA509	NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC. TBD
	LABC (5 MINS)		TBD
12:55 - 13:05	IT (10 MINS)		Invited Talk

Moderators: TBD

13:05 - 13:25	PD (20 MINS)		Panel Discussion: Track: (i) Breast Cancer - Local/Regional/Adjuvant TBD
13:25 - 13:35	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

13:35 - 14:05	(30 MINS)	LUNCH BREAK	
---------------	-----------	--------------------	--

Session 03 | Track: (i) Head & Neck

Chairperson: TBD

14:05 - 15:00	HN PLENARY (10 MINS)	LBA2	NIVOPOSTOP (CORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. TBD
	HN (5 MINS)	6001	Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). TBD
	HN (5 MINS)	6008	Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFM-ATC): A multicenter phase 2 trial. TBD
	HN (5 MINS)	6012	Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. TBD
	HN (5 MINS)	LBA6003	PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial. TBD
	HN (5 MINS)	6013	Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). TBD
	HN (5 MINS)	6015	Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naïve metastatic head and neck squamous cell carcinoma (HNSCC). TBD
	HN (5 MINS)	6018	Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial. TBD
	HN (5 MINS)	6026	Cetuximab plus dapiaciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma. TBD
	HN (5 MINS)	6027	Analysis of gene mutations, TMB, and PD-L1 in relation to ICI response in HNSCC. TBD
15:00 - 15:10	IT (10 MINS)		Invited Talk

Moderators: TBD

15:10 - 15:30	PD (20 MINS)		Panel Discussion: Track: (i) Head & Neck TBD
15:30 - 15:40	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

15:40 - 15:55	(15 MINS)	TEA BREAK	
---------------	-----------	------------------	--

Hall - 3

Session 08 | Tracks:

(i) Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allograft Transplantation | (ii) Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia | (iii) Hematologic Malignancies-Plasma Cell Dyscrasias

Chairperson: TBD

14:05 - 14:55	HLM - LMSA PLENARY (10 MINS)	LBA3	Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). TBD
	HLM - LMSA (5 MINS)	6502	Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study. TBD
	HLM - LMSA (5 MINS)	6504	An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. TBD
	HLM - LMSA (5 MINS)	7000	Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial. TBD
	HLM - LMSA (5 MINS)	7011	SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) TBD
	HLM - LMSA (5 MINS)	7015	Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. TBD
	HLM - LMSA (5 MINS)	7500	MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial. TBD

	HLM - LMSA (5 MINS)	7506	Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study. TBD
	HLM - LMSA (5 MINS)	7507	Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). TBD

Moderators: TBD

15:05 - 15:35	PD (30 MINS)		Panel Discussion: Track: (i) Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant (ii) Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia (iii) Hematologic Malignancies-Plasma Cell Dyscrasia TBD
15:35 - 15:55	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

DAY 2



24 August 2025 (Sunday)



08:00 – 17:00

SESSION HIGHLIGHTS

Time in Hrs (IST)	Track Code	Topics and Session Tracks
-------------------	------------	---------------------------

GBR - 1

08:00 - 10:00	Pre Conference Workshop - 3	Emerging Technologies in Oncology: The Role of Artificial Intelligence.
10:00 - 11:20	Scientific Session	Tracks: Gastrointestinal Cancer
11:45 - 13:05	Scientific Session	Track: Lung Cancer
13:45 - 15:05	Scientific Session	Track: Genitourinary Cancer
15:15 - 16:15	Scientific Session	Track: Gynecologic Cancer

HALL - 3

09:00 - 13:00	ASCO Poster	Award Poster Presentation - Best of ASCO, Bengaluru
15:15 - 16:35	Scientific Session	Track: Developmental Therapeutics

HALL - 4

09:00 - 17:00	Focus Session 6	Yoga
---------------	-----------------	------

HALL - 5

09:00 - 17:00	Focus Session 7	Research Methodolgy
---------------	-----------------	---------------------

HALL - 6

09:00 - 13:00	TBD	TBD
---------------	-----	-----

GBR 1

Session 04 | Tracks:

(i) Gastrointestinal Cancer–Gastroesophageal, Pancreatic, and Hepatobiliary

(ii) Gastrointestinal Cancer - Colorectal and Anal

Chairperson: TBD

10:00 - 10:50	GI PLENARY (10 MINS)	LBA4	Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). TBD
	GI (5 MINS)	4000	Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. TBD
	GI (5 MINS)	LBA4002	Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable / metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY Gastric 04 study. TBD
	GI (5 MINS)	LBA4005	PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC). TBD
	GI (5 MINS)	LBA1	Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). TBD
	GI (5 MINS)	3505	Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6). TBD
	GI (5 MINS)	LBA3500	First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses. TBD
	GI (5 MINS)		TBD
10:50 - 11:00	IT (5 MINS)		Invited Talk

Moderators: TBD

11:00 - 11:20	PD (20 MINS)		Panel Discussion: Tracks: (i) Gastrointestinal Cancer- Gastroesophageal, Pancreatic, and Hepatobiliary (ii) Gastrointestinal Cancer - Colorectal and Anal TBD
11:20 - 11:30	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

11:30 - 11:45	(15 MINS)	TEA BREAK	
---------------	-----------	------------------	--

Session 05 | Tracks:

(i) Lung Cancer–Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | (ii) Lung Cancer–Non-Small Cell Metastatic

Chairperson: TBD

11:45 - 12:35	LC PLENARY (10 MINS)	8001	Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. TBD
	LC (5 MINS)	8006	Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. TBD
	LC (5 MINS)	LBA8008	Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis (PA) of the phase 3 DeLLphi-304 trial. TBD
	LC (5 MINS)	LBA8000	Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816. TBD
	LC (5 MINS)	8503	Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab. TBD
	LC (5 MINS)	8506	Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. TBD
	LC (5 MINS)	LBA8505	Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. TBD

	LC (5 MINS)	8500	First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. TBD
	LC (5 MINS)		TBD
12:35 - 12:45	IT (5 MINS)		Invited Talk

Moderators: TBD

12:45 - 13:05	PD (20 MINS)		Panel Discussion: Tracks: (i) Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (ii) Lung Cancer-Non-Small Cell Metastatic TBD
13:05 - 13:15	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

13:15 - 13:45	(30 MINS)	LUNCH BREAK	
---------------	-----------	--------------------	--

Session 06 | Tracks:

- (i) Genitourinary Cancer–Kidney and Bladder |
(ii) Genitourinary Cancer–Prostate, Testicular, and Penile

Chairperson: TBD

13:45 - 14:35	GU (5 MINS)	4500	Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. TBD
	GU (5 MINS)	4503	Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. TBD
	GU (5 MINS)	4505	Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. TBD
	GU (5 MINS)	4514	Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). TBD
	GU (5 MINS)	4517	Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study. TBD

	GU (5 MINS)	5001	Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE. TBD
	GU (5 MINS)	LBA5006	Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. TBD
	GU (5 MINS)	5002	Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry. TBD
	GU (5 MINS)	5003	Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials. TBD
	GU (5 MINS)	5007	A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis. TBD
14:35 - 14:45	IT (10 MINS)		Invited Talk

Moderators: TBD

14:45 - 15:05	PD (20 MINS)		Panel Discussion: Track: Genitourinary Cancer TBD
15:05 - 15:15	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

Session 07 | Tracks: (i) Gynecologic Cancer

Chairperson: TBD

15:15 - 16:05	GY (5 MINS)	LBA5500	TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). TBD
	GY (5 MINS)	LBA5504	Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. TBD

15:15 - 16:05	GY (5 MINS)	5510	Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study. TBD
	GY (5 MINS)	LBA5501	Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial. TBD
	GY (5 MINS)	5502	Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses. TBD
	GY (5 MINS)	5531	A real-world analysis of the effectiveness of pembrolizumab by type of associated treatment in patients with metastatic cervical cancer: Added value of bevacizumab. TBD
	GY (5 MINS)	5546	Development and validation of a proteo-metabolic panel for detection of asymptomatic ovarian cancer with minimal serum sample requirements: A multi-center prospective study. TBD
	GY (5 MINS)	5583	Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advancedstage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. TBD
	GY (5 MINS)	5554	Final analysis of SCORES, a phase III randomized, double-blinded, placebocontrolled study of suvemcitug combined with chemotherapy for platinumresistant ovarian cancer. TBD
	GY (5 MINS)	LBA5507	ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). TBD
16:05 - 16:15	IT (10 MINS)		Invited Talk

Moderators: TBD

16:15 - 16:35	PD (20 MINS)		Panel Discussion: Track: Gynecologic Cancer TBD
16:35 - 16:45	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

Hall - 3

Session 09 | Tracks:

(i) Developmental Therapeutics - Immunotherapy (ii) Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

Chairperson: TBD

15:15 - 15:45	DT-I (5 MINS)	2501	First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors. TBD
	DT-I (5 MINS)	2513	Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy. TBD
	DT-I (5 MINS)	2511	Safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients: A systematic review and individual patient data meta-analysis. TBD
	DT-I (5 MINS)	3001	Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations. TBD
	DT-I (5 MINS)	3002	Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC). TBD
	DT-I (5 MINS)	3006	Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. TBD
15:45 - 15:55	IT (10 MINS)		Invited Talk

Moderators: TBD

15:55 - 16:15	PD (30 MINS)		Panel Discussion: Track: (i) Developmental Therapeutics - Immunotherapy (ii) Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology TBD
16:15 - 16:35	IS (10 MINS)		Industry Session by TBD: Topic TBD TBD

BEST OF ASCO[®]

OFFICIALLY LICENSED

AMERICAN SOCIETY OF CLINICAL ONCOLOGY
BENGALURU, INDIA 2025

Endorsed by



Academia of Head & Neck
Oncology of Karnataka

Hosted by



CONTACT US



Mr. Gautam Menon | +91 9731853344
Mrs. Sushma Pal | +91 8951770391



ascoindia@globalhealthcareacademy.in



www.globalhealthcareacademy.in/bestofasco

